<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181112041616N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-28</date_registration>
      <primary_sponsor>Jeeroft University of Medical Sciences</primary_sponsor>
      <public_title>The effect of dexamethasone on antiemetics</public_title>
      <acronym></acronym>
      <scientific_title>The effect of dexamethasone on antiemetic use after pelvic and femoral surgery in patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72276</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Randomization description: A code of 1 to 140 is considered for each questionnaire. And the random assignment is that we consider two groups named A and B, after that we put even numbers in group A and odd numbers in group B, and finally one group is called intervention and the other group. We consider it as control, Blinding description: Participants, principal investigator, physicians, nurses, orthopedic surgeons, data collection and outcome assessors, and the data safety and monitoring committee.</study_design>
      <phase>3</phase>
      <hc_freetext>Hip and femur surgery.</hc_freetext>
      <i_freetext>Intervention group: Before the operation, patients in both groups will receive a single oral dose of acetaminophen 1000 mg and pregabalin 100 mg. In the intervention group, patients will receive 10 mg of dexamethasone intravenously in 90 minutes after surgery. A local infiltration cocktail of 62 ml was injected during the operation, which consists of the following drugs: Also, in both groups, all patients during the first 24 hours after the operation, (3 mg/kg and the maximum dose of 300 mg, 60 ml) 0.5% ropivacaine , will receive 30 mg (1 ml) of ketorolac and 5 mac/kg of epinephrine. Analgesics: acetaminophen 1000 mg orally every 8 hours, oxycodone 5 mg orally every 12 hours as needed for moderate pain or 10 mg for severe pain, meloxicam 7.5 mg orally every 12 hours, gabapentin 100 mg orally every 12 hours 12 hours and diazepam 5 mg orally as needed for muscle spasms. In addition, patients in both groups will receive more opioid analgesics as needed. If necessary, intravenous doses of four milligrams of ondansetron will be prescribed every 4-6 hours to control post-operative nausea and vomiting (PONV). Prochloroprazine will be used as a secondary antiemetic. Complications such as readmission, infection, reoperation, dislocation, venous thrombosis, pulmonary embolism, pneumonia and other post-operative cases are also investigated.To collect medical records information: age, sex, body mass index, type of surgery, smoking status, diabetes status and measurement of glycosylated hemoglobin less than 3 months before surgery will be used..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "There is no further information".</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>دکتر سینا حیدری</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Square - Imam Khomeini Hospital</address>
        <city>Jiroft</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7861634200</zip>
        <telephone>+98 34 4331 7302</telephone>
        <email>ehsanmovahed89@yahoo.com</email>
        <affiliation>Jeeroft University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Yasin Sohrani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Square - Imam Khomeini Hospital</address>
        <city>Jiroft</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7861634200</zip>
        <telephone>+98 34 4331 7302</telephone>
        <email>ehsanmovahed89@yahoo.com</email>
        <affiliation>Jeeroft University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients over 18 years old in 2022 who undergo hip and femur surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who are undergoing surgery or have a recent history of pregnancy, use steroid or immunosuppressant drugs within 6 months after kidney or liver surgery, and have drug and alcohol abuse.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M95-M99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acquired deformities of musculoskeletal system and connective tissue</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Before the operation, patients in both groups will receive a single oral dose of acetaminophen 1000 mg and pregabalin 100 mg. In the intervention group, patients will receive 10 mg of dexamethasone intravenously in 90 minutes after surgery. A local infiltration cocktail of 62 ml was injected during the operation, which consists of the following drugs: Also, in both groups, all patients during the first 24 hours after the operation, (3 mg/kg and the maximum dose of 300 mg, 60 ml) 0.5% ropivacaine , will receive 30 mg (1 ml) of ketorolac and 5 mac/kg of epinephrine. Analgesics: acetaminophen 1000 mg orally every 8 hours, oxycodone 5 mg orally every 12 hours as needed for moderate pain or 10 mg for severe pain, meloxicam 7.5 mg orally every 12 hours, gabapentin 100 mg orally every 12 hours 12 hours and diazepam 5 mg orally as needed for muscle spasms. In addition, patients in both groups will receive more opioid analgesics as needed. If necessary, intravenous doses of four milligrams of ondansetron will be prescribed every 4-6 hours to control post-operative nausea and vomiting (PONV). Prochloroprazine will be used as a secondary antiemetic. Complications such as readmission, infection, reoperation, dislocation, venous thrombosis, pulmonary embolism, pneumonia and other post-operative cases are also investigated.To collect medical records information: age, sex, body mass index, type of surgery, smoking status, diabetes status and measurement of glycosylated hemoglobin less than 3 months before surgery will be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score scale, use of antiemetic drug after surgery. Timepoint: Oxycodone 5 mg orally every 12 hours for moderate pain and 4 mg of ondansetron postoperatively every 4-6 hours to control nausea and vomiting. Method of measurement: Oxycodone 5 mg orally every 12 hours for moderate pain and 4 mg of ondansetron postoperatively every 4-6 hours to control nausea and vomiting.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Jeeroft University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-27</approval_date>
        <contact_name>کمیته اخلاق دانشگاه علوم پزشکی جیرفت</contact_name>
        <contact_address>Shahid Square - Jiroft University of Medical Sciences Jiroft Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
